Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines

Biomedicine and Pharmacotherapy

Volumn 68, Issue 1, 2014, Pages 111-117

  Januchowski, Radosław ^a   Wojtowicz, Karolina ^a   Andrzejewska, Małgorzata ^a   Zabel, Maciej ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Drug transporters; Drug resistant cancer; Expression levels; MDR3

Indexed keywords

DRUG TRANSPORTERS; DRUG-RESISTANT CANCER; EXPRESSION LEVELS; MDR3;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; VINCRISTINE;

EID: 84895068588     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.09.004     Document Type: Article

References (21)

1. Stavrovskaya A.A. Cellular mechanism of multidrug resistance of tumor cells. Biochemistry 2000, 65(1):95-106.
2. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2(1):48-58.
3. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424.
4. Horwitz S.B., Cohen D., Rao S., Ringel I., Shen H.J., Yang C.P. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993, 15:55-61.
5. Ford J.M., Bruggemann E.P., Pastan I., Gottesman M.M., Hait W.N. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 1990, 50(6):1748-1756.
6. Bellamy W.T., Dalton W.S. Multidrug resistance in the laboratory and clinic. Adv Clin Chem 1994, 31:1-61.
7. Chin J.E., Soffir R., Noonan K.E., Choi K., Robinson I.B. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989, 9(9):3808-3820.
8. Lincke C.R., Smit J.J.M., van der Velde-Koerts T., Borst P. Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 1991, 266(8):5303-5310.
9. Smith A.J., Timmermans-Hereijgers J.L.P.M., Roelofsen B., Wirtz K.W.A., van Blitterswijk W.J., Smit J.J.M., et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 1994, 354(11):263-266.
10. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996, 87(3):507-517.
11. Nooter K., Sonneveld P., Janssen A., Oostrum R., Boersma T., Herweijer H., et al. Expression of the MDR3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer 1990, 45(4):626-631.
12. Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of MDRl and MDR3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990, 82(13):1133-1140.
13. Sonneveld P., Nooter K., Burghouts J.T.M., Herweijer H., Adriaansen H.J., Dongen J.J.M. High expression of MDR3 multidrug resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992, 79(6):1496-1500.
14. Arai Y., Masuda M., Sugawara I., Arai T., Motoji T., Tsuruo T., et al. Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. Leuk Res 1997, 21(4):313-319.
15. Citti A., Boldrini R., Inserra A., Alisi A., Pessolano R., Mastronuzzi A., et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. Int J Oncol 2012, 41(1):117-124.
16. Duan Z., Brakora K.A., Seiden M.V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004, 3(7):833-838.
17. Smith A.J., van Helvoort A., van Meer G., Szabo K., Welker E., Szakacs G., et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000, 275(31):23530-23539.
18. Devault A., Gros P. Two members of the mouse MDR gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990, 10(4):1652-1663.
19. Dietel M., Bals U., Schaefer B., Herzig I., Arps H., Zabel M. In vitro prediction of cytostatic drug resistance in primary cell cultures of solid malignant tumours. Eur J Cancer 1993, 29A(3):416-420.
20. Duan Z., Lamendola D.E., Duan Y., Yusuf R.Z., Seiden M.V. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005, 55(3):277-285.
21. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003, 3(1):1-19.